Adaptive Symptom Self-Management Immunotherapy Study

The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.

NCT Number	NCT05715255
Lead Sponsor	University of Arizona Collaborators: National Cancer Institute (NCI)
Conditions	Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Enrollment	400 participants
Start Date	2023-05-08
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-31